ישראל - עברית - Ministry of Health

sanofi israel ltd - sarilumab - תמיסה להזרקה - sarilumab 131.6 mg / 1 ml - sarilumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - sarilumab - תמיסה להזרקה - sarilumab 175 mg / 1 ml - sarilumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - faricimab - תמיסה להזרקה - faricimab 120 mg/ml - faricimab

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 150 mg/ml - dupilumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 175 mg/ml - dupilumab

ישראל - עברית - Ministry of Health

merck serono ltd - avelumab - תרכיז להכנת תמיסה לאינפוזיה - avelumab 20 mg / 1 ml

ישראל - עברית - Ministry of Health

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 100 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

ישראל - עברית - Ministry of Health

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 400 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 100 mg - imatinib

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 400 mg - imatinib